Receptos bowel disorder drug meets mid-stage trial goal

(Reuters) - Receptos Inc said its experimental ulcerative colitis drug met the main goal in a mid-stage trial, sending its shares up 30 percent. Receptos' study tested the safety and efficacy in two doses of its lead drug, RPC1063, against a placebo in 199 patients with ulcerative colitis. During the study, 16.4 percent patients treated in the 1 mg dose group met the main goal of clinical remission at the eighth week, compared with 6.2 percent in the placebo group. The company plans to begin a late-stage study of the drug in 2015. ... via Health News Headlines - Yahoo News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/1wEIkMs